新型选择性吗啉类TAAR1部分激动剂对神经精神障碍的临床前效应及健康志愿者耐受性
本文报道新型选择性吗啉类痕量胺相关受体1(TAAR1)部分激动剂RO6799477和RO6889450的临床前与I期临床研究。二者在啮齿类模型中显示抗精神病、应激调节和抗成瘾样活性,且神经激活模式不同于第一、二代抗精神病药。健康志愿者I期研究显示RO6799477耐受良好但高剂量出现神经和心血管不良事件,RO6889450在300 mg以内耐受良好、450 mg出现剂量限制性不良事件。
要点
- RO6799477和RO6889450为选择性TAAR1部分激动剂,临床前显示抗精神病、应激调节及抗成瘾样活性。
- RO6889450非临床滥用倾向研究显示有利的低滥用潜力特征,提示缺乏强化效应。
- 健康志愿者I期:RO6799477高剂量致神经和心血管不良事件;RO6889450 450 mg出现体位性心动过速和红斑等剂量限制性事件。
核心结论
- 新型选择性吗啉类TAAR1部分激动剂RO6799477和RO6889450具有转化潜力,支持进一步临床探索作为神经精神障碍特别是精神分裂症和物质使用障碍的新型治疗选择。
研究设计与样本
- 临床前研究在啮齿类模型中评估RO6799477和RO6889450的药理作用,并开展非临床药物滥用倾向研究和临床前安全性研究。
- 两项化合物均进入健康志愿者I期单次和多次递增剂量研究。
主要发现
- RO6799477和RO6889450在啮齿类模型中减少PCP和可卡因诱导的高活动,增强奥氮平效应,部分逆转可卡因对颅内自我刺激的促进作用,并在应激诱导高热试验中显示抗焦虑样特性。
- 药理学MRI测量的神经激活模式不同于第一代和第二代抗精神病药。
- RO6889450非临床滥用倾向研究显示有利的低滥用潜力特征并提示缺乏强化效应。
- RO6799477在健康志愿者中耐受良好,吸收迅速、药代动力学呈剂量比例,但较高剂量导致神经和心血管不良事件。
- RO6889450在健康志愿者中至300 mg耐受良好,450 mg时剂量限制性不良事件包括体位性心动过速和红斑。
关键数值与推荐
- RO6889450在健康志愿者中耐受良好至300 mg剂量。
- RO6889450在450 mg剂量时出现剂量限制性不良事件,包括体位性心动过速和红斑。
- RO6799477在健康志愿者中吸收迅速且药代动力学呈剂量比例。
临床怎么用
- TAAR1部分激动剂作为新机制药物,临床前数据支持针对精神分裂症和物质使用障碍进一步开展临床研究。
- I期安全性结果显示RO6799477高剂量需监测神经和心血管不良事件,RO6889450需关注450 mg时体位性心动过速和红斑。
局限性
- 原文未报告所述临床前和I期研究的具体样本量、置信区间和P值。
- RO5263397因UGT2B10剪接位点突变个体中N-葡萄糖醛酸化代谢不良而停止开发,提示TAAR1激动剂开发需考虑代谢基因多态性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trace amine-associated receptor 1 (TAAR1) is a novel target for antipsychotic and potentially mood-stabilizing and anti-addictive drugs, offering a new mechanism by modulating dopaminergic, serotonergic, and glutamatergic neurotransmission. TAAR1 agonists from a prior amino oxazolines series were studied preclinically and clinically, but development of partial agonist RO5263397 was halted due to poor metabolization by N-glucuronidation in individuals with UGT2B10 splice site mutations. A medicinal chemistry program subsequently identified new potent and selective TAAR1 ligands from the morpholine series. Two selective partial agonists, RO6799477 and RO6889450, were advanced and showed antipsychotic, stress-response-modulating, and anti-addictive-like activity in rodent models. They reduced PCP- and cocaine-induced hyperlocomotion, potentiated olanzapine's effect, partially reversed cocaine-induced facilitation of intracranial self-stimulation and demonstrated anxiolytic-like properties in the stress-induced hyperthermia test. Neural activation profiles, measured by pharmacological MRI, differed from first and second-generation antipsychotics. Non-clinical drug abuse liability studies with RO6889450 indicated a favorable low abuse liability profile and suggested a lack of reinforcing effects. Preclinical safety studies indicated a favorable profile with clinically monitorable and reversible findings. Both compounds progressed into Phase I single and multiple ascending dose studies in healthy volunteers. RO6799477 was well tolerated, with rapid absorption and dose-proportional pharmacokinetics, though higher doses led to nervous system and cardiovascular adverse events. RO6889450 was well tolerated up to 300 mg; at 450 mg, dose-limiting adverse events included postural tachycardia and erythema. Together, these results indicate the translational potential and support further clinical exploration of TAAR1 agonists as a novel therapeutic option for neuropsychiatric disorders, particularly schizophrenia and substance use disorder.
引用
- Fournier C, Buchy D, Mohr S, et al. Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteers. Mol Psychiatry. 2026. PMID: 41639230. doi:10.1038/s41380-026-03465-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。